Home > Search Results

Results: 5

Clear

The review concluded that the maintenance or the consolidation therapy approach failed to improve the outcomes of small-cell lung cancer. A survival advantage was suggested for maintenance chemotherapy and interferon-alpha, but further research is needed. The authors' conclusions were suitably cautious and are likely to be reliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2010

The authors concluded that single-agent gemcitabine continues to be the standard of care for patients with advanced, inoperable pancreatic adenocarcinoma, although platinum-gemcitabine could be considered in certain patients. Limitations of the included studies and review make it difficult to determine the reliability of these conclusions, although the authors' suggestion to revise approaches to research in pancreatic cancer seems reasonable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2007

This review concluded that use of available molecular-targeted therapies combined with gemcitabine was not supported for treating advanced pancreatic cancer as they did not significantly benefit overall survival and were associated with higher grade toxicities compared with gemcitabine alone. The authors' conclusions should be treated cautiously given the small number of included trials and the diverse molecular-targeted therapies studied.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

This review concluded that there were many options for first and subsequent lines of therapy, including chemotherapy and targeted therapies, that have comparable efficacy in advanced breast cancer. Overall, the authors' conclusions appear valid, but the lack of any assessment of trial quality and the use of both direct and indirect evidence, suggests that the findings should be interpreted cautiously.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2008

This review concluded that, compared with gemcitabine monotherapy, gemcitabine-based combination therapy may improve survival in patients with advanced pancreatic cancer. The review was generally well conducted and the authors’ conclusions appear justified, however, the clinical significance of the findings is unclear.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2006

Systematic Reviews in PubMed

See all (2)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...